财务业绩 - 总收入为6.372亿美元，其中卡博坎替尼系列在美国的净产品收入为4.376亿美元[3] - 非美国通用会计准则下的每股摊薄收益为0.84美元[14] - 公司第二季度GAAP净收入为2.26亿美元，同比增长178%[47] - 第二季度非GAAP净收入为2.46亿美元，同比增长145%[47] - 第二季度GAAP每股收益为0.77美元，非GAAP每股收益为0.84美元[47] - 上半年GAAP净收入为2.63亿美元，同比增长117%[47] - 上半年非GAAP净收入为2.98亿美元，同比增长94%[47] - 上半年GAAP每股收益为0.88美元，非GAAP每股收益为0.99美元[47] 产品管线进展 - FDA受理卡博坎替尼用于治疗晚期神经内分泌肿瘤的补充新药申请，并给予标准审查，目标审查日期为2025年4月3日[24] - 完成STELLAR-303期三试验的患者入组，并计划启动STELLAR-311期三试验评估zanzalintinib治疗神经内分泌肿瘤[29] - 启动XB010单抗偶联药物的首次人体试验[30] - 决定终止XB002的开发[31] 商业合作 - 从Ipsen公司获得1.5亿美元的销售里程碑付款[23] - 与Cipla有关的CABOMETYX专利诉讼达成和解[34] 股票回购 - 完成4.5亿美元的股票回购计划，并宣布新的最高5亿美元的股票回购计划[3] - 完成450百万美元的2024年股票回购计划[35] - 宣布新的500百万美元股票回购计划至2025年底[36] 其他 - 卡博坎替尼在美国和全球的商业表现强劲[5] - 公司采用52或53周的财年制[37] - 将于8月6日召开2024年第二季度财报电话会议[38][39] - 第二季度研发费用中的股票期权费用为917.8万美元[47] - 第二季度销售、一般及管理费用中的股票期权费用为1617.6万美元[47] - 上述股票期权费用调整后的税收影响为584.1万美元[47] - 上半年研发费用中的股票期权费用为1307万美元，销售及管理费用中的为3139.7万美元[47]

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. Estimate Revisions Trend The earnings report, which is expected to be released on August 6, 2024, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. This drug ...

Exelixis, Inc. (EXEL) entered into a settlement agreement with Cipla, which was looking to market a generic version of Cabometyx (cabozantinib). Cabometyx is Exelixis' lead drug. The settlement agreement resolves two patent litigations brought by Exelixis in response to Cipla's abbreviated new drug application (ANDA). The ANDA is seeking approval to market generic versions of Cabometyx tablets prior to the expiration of the applicable patents. The first case relates to Cipla's ANDA for a 60 mg cabozantinib ...

These stocks are both experts in their respective fields.Many billionaire investors are going all in on artificial intelligence (AI). That's understandable. AI is quickly being integrated into businesses' day-to-day operations. The leaders in the field could deliver outsized returns. However, there are other exciting investment opportunities out there. Consider Renaissance Technologies, a hedge fund headed by Jim Simons. The fund's holdings feature several healthcare stocks. That includes two notable drugma ...

Have you assessed how the international operations of Exelixis (EXEL) performed in the quarter ended March 2024? For this drug developer, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors now place great importan ...

Exelixis, Inc. (EXEL) reported lower-than-expected results for the first quarter. Its shares fell 7% in after-hours trading following the announcement.EXEL recorded earnings of 17 cents per share, which missed the Zacks Consensus Estimate of 28 cents. The company registered adjusted earnings of 16 cents per share in the first quarter of 2023.Including stock-based compensation expense, EPS was 12 cents, flat year over year.Net revenues were $425.2 million, which lagged the Zacks Consensus Estimate of $468 mi ...

财务数据和关键指标变化 - 第一季度2024年Cabo系列产品净销售收入同比增长4% [1][2] - 全球Cabo系列产品净销售收入同比增长约9% [1] - 第一季度2024年总收入约4.25亿美元 [3] - 第一季度2024年毛利率为32.9%,略高于2023年第四季度 [3] - 第一季度2024年GAAP净收益约3700万美元,非GAAP净收益约5200万美元 [3] - 截至2024年3月31日,现金及投资约16亿美元 [3] - 公司在第一季度回购了约1.91亿美元的股票 [3] 各条业务线数据和关键指标变化 - CABOMETYX处方量同比增长4%,而TKI市场整体持平 [4] - CABOMETYX在肾细胞癌一线IO-TKI市场和二线单药市场保持领先地位 [1] 各个市场数据和关键指标变化 - 肾细胞癌一线IO-TKI市场竞争激烈,CABOMETYX联合nivolumab仍是该市场的第一大处方 [4] - 肝细胞癌二线市场,CABOMETYX仍是市场领导者 [4] 公司战略和发展方向及行业竞争 - 公司将重点推进Cabo在神经内分泌瘤和转移性去势抵抗性前列腺癌的新适应症,以及Zanza的临床开发 [1][4] - 公司正在积极探索与其他公司进行成本和化合物共享的合作机会 [1] - 公司正在审慎评估整个企业范围内的竞争格局,以识别可能适合公司GU和GI肿瘤业务的后期阶段资产 [1] 管理层对经营环境和未来前景的评论 - 公司在2024年第一季度取得了强劲的开局,各业务部门都取得了丰硕的成果 [1] - Cabo系列产品在美国和全球范围内的需求和收入都在持续增长 [1] - 公司正在积极推进Cabo和Zanza以及管线中其他令人兴奋的候选药物的开发,以改善癌症患者的标准治疗 [1] - 公司对Zanza的潜力感到非常兴奋,认为其具有最佳-in-class的VEGFR-TKI潜力 [5][6] 问答环节重要的提问和回答 问题1 **Joe Catanzaro 提问** 如果Cabo专利诉讼有积极结果,公司是否会寻找后期阶段的资产,以及公司的资产规模和交易能力如何 [7] **Michael Morrissey 回答** 公司一直在寻找后期阶段的资产,包括已经进入关键试验或即将进入的资产,无论是小分子还是生物制剂,这都符合公司的GU和GI肿瘤业务发展平台 [7] 公司有充足的现金流和资产规模,可以进行此类交易,具体规模公司不会透露 [7] 问题2 **Jason Gerberry 提问** 公司如何看待神经内分泌瘤适应症的商业机会,是否存在一些挑战,如需要重新培训医生等 [9] **P.J. Haley 回答** 公司对神经内分泌瘤的数据非常兴奋,不认为会有与之前新适应症上市大不相同的挑战,医生对TKI已经很熟悉 [9] 公司研究的人群覆盖广泛,包括胰腺、肺等来源的肿瘤,SSTR阳性或阴性,以及既往接受过Lutathera治疗的患者,这使Cabo有望覆盖广泛的神经内分泌瘤患者群体 [9] 问题3 **Amy Peterson 回答** 公司正在密切关注LEAP-010的数据,并据此适当调整STELLAR-305的设计,以提高成功概率 [11] Zanza的作用机制与LEN不同,有望在头颈鳞状细胞癌患者群体中取得更好的疗效 [11]

For the quarter ended March 2024, Exelixis (EXEL) reported revenue of $425.23 million, up 4% over the same period last year. EPS came in at $0.17, compared to $0.16 in the year-ago quarter.The reported revenue represents a surprise of -9.07% over the Zacks Consensus Estimate of $467.64 million. With the consensus EPS estimate being $0.28, the EPS surprise was -39.29%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their n ...

财务业绩 - 第一季度总收入为4.252亿美元，同比增长4%[35] - 产品销售收入为3.785亿美元，同比增长4%[39] - 许可收入为4,467.6万美元，同比增长17%[39] - 非GAAP净利润为5,198.2万美元，同比减少2%[40] - 基于非GAAP的每股收益为0.17美元，同比增长6%[40] 研发及营销费用 - 研发费用为2.277亿美元，同比减少3%[39] - 销售及管理费用为1.140亿美元，同比减少13%[39] 重组费用 - 重组费用为3,283.5万美元[39] 股票回购 - 公司董事会批准了额外4.5亿美元的股票回购计划[24][26] - 公司计划在2024年内回购最多4.5亿美元的股票[36] 新药研发 - 公司计划在2024年提交3个新药物的IND申请[23] - 公司计划在2024年ASCO年会上发表关于卡博替尼和赞扎利替尼的临床数据[36] 产品销售 - 卡博坦汀系列在美国的净产品收入为3.785亿美元，其中CABOMETYX为3.764亿美元,COMETRIQ为210万美元[17] - 卡博坦汀在美国以外地区的销售产生的特许权使用费收入为3,960万美元[17] 临床试验结果 - 第三期CONTACT-02临床试验显示卡博坦汀联合阿特朱单抗在转移性去势抵抗性前列腺癌患者中显著改善无进展生存期[18][20] - CheckMate-9ER试验4年随访结果显示卡博坦汀联合纳武单抗在既往未治疗的肾细胞癌患者中持续显示优于舒尼替尼的疗效[21]

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Regeneron (REGN) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with p ...